Peritoneal Mesothelioma clinical trials

Explore recruiting peritoneal mesothelioma clinical trials.

Recruiting peritoneal mesothelioma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Peritoneal Mesothelioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TALAMESO : A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma

France

Therapeutic exploratory (Phase II) EU CTIS Study details

IMMUNOPEC: Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with Peritoneal Mesothelioma

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas

Spain, Poland, Italy, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Peritoneal Mesothelioma trials by city

Peritoneal Mesothelioma in Toronto Peritoneal Mesothelioma in Vancouver Peritoneal Mesothelioma in Montreal Peritoneal Mesothelioma in Calgary Peritoneal Mesothelioma in Edmonton Peritoneal Mesothelioma in Ottawa Peritoneal Mesothelioma in Winnipeg Peritoneal Mesothelioma in Quebec City Peritoneal Mesothelioma in Hamilton Peritoneal Mesothelioma in Kitchener Peritoneal Mesothelioma in London Peritoneal Mesothelioma in Halifax Peritoneal Mesothelioma in New York Peritoneal Mesothelioma in Los Angeles Peritoneal Mesothelioma in Chicago Peritoneal Mesothelioma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease